Aberdeen Group plc Has $12.46 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Aberdeen Group plc lessened its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 8.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 632,441 shares of the biopharmaceutical company’s stock after selling 56,319 shares during the period. Aberdeen Group plc owned 0.52% of Catalyst Pharmaceuticals worth $12,459,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CPRX. Jones Financial Companies Lllp raised its stake in Catalyst Pharmaceuticals by 14.0% during the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after acquiring an additional 498 shares in the last quarter. Mission Wealth Management LP boosted its stake in shares of Catalyst Pharmaceuticals by 5.0% during the second quarter. Mission Wealth Management LP now owns 10,620 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 510 shares in the last quarter. Amalgamated Bank boosted its position in Catalyst Pharmaceuticals by 2.0% during the 2nd quarter. Amalgamated Bank now owns 32,619 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 654 shares during the period. Huntington National Bank grew its holdings in Catalyst Pharmaceuticals by 105.0% during the 2nd quarter. Huntington National Bank now owns 1,433 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 734 shares during the last quarter. Finally, HBK Sorce Advisory LLC increased its position in Catalyst Pharmaceuticals by 6.9% in the 3rd quarter. HBK Sorce Advisory LLC now owns 11,958 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 768 shares during the period. 79.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on CPRX shares. Oppenheimer reiterated an “outperform” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Citigroup increased their price target on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Wall Street Zen upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average target price of $33.20.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $24.42 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $26.58. The stock has a 50 day moving average price of $23.82 and a two-hundred day moving average price of $22.06. The stock has a market capitalization of $3.00 billion, a PE ratio of 14.20, a price-to-earnings-growth ratio of 0.81 and a beta of 0.74.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Carmen Jeffrey Del sold 10,983 shares of the business’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $23.33, for a total value of $256,233.39. Following the transaction, the insider directly owned 3,962 shares of the company’s stock, valued at approximately $92,433.46. The trade was a 73.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Molly Harper sold 26,746 shares of the stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total transaction of $621,844.50. Following the transaction, the director owned 2,360 shares of the company’s stock, valued at approximately $54,870. The trade was a 91.89% decrease in their position. The SEC filing for this sale provides additional information. 10.40% of the stock is owned by company insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).